No­var­tis' Cosen­tyx miss­es main goal in head-to-head tri­al with Ab­b­Vie's Hu­mi­ra

Af­ter re­port­ing pos­i­tive da­ta in non-ra­di­ograph­ic ax­i­al spondy­loarthri­tis last month, No­var­tis’ block­buster Cosen­tyx was dealt a set­back on Fri­day.

In the 52-week EX­CEED tri­al in 800 bi­o­log­ic-naïve ac­tive pso­ri­at­ic arthri­tis pa­tients, the IL-17A drug was test­ed against Ab­b­Vie’s flag­ship Hu­mi­ra. The main goal of the study was to show Cosen­tyx was sta­tis­ti­cal­ly su­pe­ri­or us­ing re­sponse rates to ACR20, a stan­dard mea­sure that looks for a 20% re­cov­ery in the num­ber of ten­der and num­ber of swollen joints, and a 20% im­prove­ment in three oth­er cat­e­gories at week 52.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER